MedicinalProductInteraction.management
FHIR attribute (r4)
In the MedicinalProductInteraction resource for FHIR r4 , the management attribute identifies the Actions for managing the interaction
management (MedicinalProductInteraction) description
Resource Type: MedicinalProductInteraction
Attribute Name: management
Description: Actions for managing the interaction
FHIR Version: r4
Attribute Type : CodeableConcept
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
MedicinalProductInteraction.management Example
"management": {
"text": "Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"
}MedicinalProductInteraction attributes
AttributeField is listTypeDescription
Description: The medication for which this is a described interaction
FHIR Version: r4
Attribute Type : Reference
Required: N/A
Countability: Array
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"subject": Learn more about the (MedicinalProductInteraction) subject FHIR attribute
Description: The interaction described
FHIR Version: r4
Attribute Type : string
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"description": "Inhibitors of CYP3A4 and P-gp\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\nequixaban Cmax.\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\nsection 4.4).\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp."Learn more about the (MedicinalProductInteraction) description FHIR attribute
Description: The specific medication, food or laboratory test that interacts
FHIR Version: r4
Attribute Type : Data Type
Required: N/A
Countability: Array
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"interactant": [
{
"itemCodeableConcept": {
"coding": [
{
"system": "http://ema.europa.eu/example/interactant",
"code": "ketoconazole"
}
]
}
},
{
"itemCodeableConcept": {
"coding": [
{
"system": "http://ema.europa.eu/example/interactant",
"code": "itraconazole"
}
]
}
}
]Learn more about the (MedicinalProductInteraction) interactant FHIR attribute
Description: The type of the interaction e.g. drug-drug interaction, drug-food interaction, drug-lab test interaction
FHIR Version: r4
Attribute Type : CodeableConcept
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"type": {
"coding": [
{
"system": "http://ema.europa.eu/example/interactionsType",
"code": "StrongInhibitorofCYP3A4"
}
]
}Learn more about the (MedicinalProductInteraction) type FHIR attribute
Description: The effect of the interaction, for example "reduced gastric absorption of primary medication"
FHIR Version: r4
Attribute Type : CodeableConcept
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"effect": {
"coding": [
{
"system": "http://ema.europa.eu/example/interactionseffect",
"code": "Increasedplasmaconcentrations"
}
]
}Learn more about the (MedicinalProductInteraction) effect FHIR attribute
Description: The incidence of the interaction, e.g. theoretical, observed
FHIR Version: r4
Attribute Type : CodeableConcept
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"incidence": Learn more about the (MedicinalProductInteraction) incidence FHIR attribute
Description: Actions for managing the interaction
FHIR Version: r4
Attribute Type : CodeableConcept
Required: N/A
Countability: Singleton
Flags: N/A
Terminology bindings: N/A
Requirements: N/A
Comments: N/A
Example:
"management": {
"text": "Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"
}Learn more about the (MedicinalProductInteraction) management FHIR attribute
